LENSKART · NSE
Lenskart Solutions Limited
₹744.35
+0.36% (+₹2.7)
Prev. close
₹741.65
Volume
32,60,264
Delivery %
75.7%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
4 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
2 · 2 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Nomura is bullish on Lenskart Solutions with a target price of ₹888, implying a 32% upside. The brokerage expects Lenska…” | Nomura AnalysisNomura Global Markets Research | Lenskart Solutions | PENDING | |
| “Bullish on Lenskart Solutions for intraday trading, recommending a buy at ₹662 with a target price of ₹716 and a stop lo…” | Sumeet BagadiaChoice Equity Broking | Lenskart Solutions | MISS | |
| “Macquarie initiated coverage on Lenskart with an Outperform rating and a target price of Rs 530, implying a nearly 30% u…” | Macquarie AnalysisMacquarie Capital Securities | Lenskart Solutions | HIT | |
| “Assigned a 'Buy' rating on Lenskart, setting a share price target of ₹500, indicating a potential 23% upside. The broker…” | Jefferies AnalysisJefferies | Lenskart Solutions | HIT | |
| “Initiated coverage with a Buy rating on Lenskart, setting a price target of ₹500. The brokerage highlights India's massi…” | Jefferies AnalysisJefferies | Lenskart | HIT | |
| “Initiated coverage on Lenskart with a 'buy' rating and a target price of ₹500, citing strong growth potential in India's…” | Jefferies AnalysisJefferies | Lenskart | HIT | |
| “Initiated coverage on Lenskart with a 'Buy' rating and a target price of ₹500, implying a nearly 23% upside from its pre…” | Jefferies AnalysisJefferies | Lenskart | HIT | |
| “Initiated coverage on Lenskart Solutions with a Buy rating, projecting a 23% upside to a ₹500 price target. This bullish…” | Jefferies AnalysisJefferies | Lenskart Solutions | HIT |
Market commentary · 4 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Overweight rating on Lenskart Solutions, priced at Rs 524 with a market capitalization of $10 billion.” | Morgan Stanley AnalysisMorgan Stanley India | Lenskart Solutions | — | |
| “Bullish on Lenskart, believing it has built a differentiated retail model and a full-stack eyewear ecosystem. The broker…” | Elara Capital AnalysisElara Capital | Lenskart | — | |
| “Expects Lenskart to report steady revenue expansion of 20-25% year-on-year for Q2, building on Q1 FY26's performance. He…” | Nitin JainBonanza | Lenskart | — | |
| “Advises investors who have been allotted Lenskart shares to hold them for the medium to long term, supported by strong e…” | Shivani NyatiSwastika Investmart Ltd. | Lenskart Solutions | — |
Fundamentals
About Lenskart Solutions Limited
Lenskart Solutions Limited, a technology-driven eyewear company, engages in designing, manufacturing, branding, and retailing of eyewear products in India, Japan, Southeast Asia, the Middle East, and internationally. Its products include prescription eyeglasses, sunglasses, goggles, screen glasses, and other products, such as contact lenses and eyewear accessories, including frames for men, women, and kids. The company also engages in lens manufacturing, lens edging, lens design, frame design, frame manufacturing, and delivery. It operates as a direct-to-consumer company that designs and sells a wide range of eyewear products under the Lenskart and Owndays brands; and sub brands, including John Jacobs, Vincent Chase, Hooper, Lenskart Air, Hustlr, LPL, and Meller. It sells its products through online and offline channels, such as retail stores, websites, mobile applications, and other channels. The company also owns and operates eyewear retail stores in India and provides home eye check-up services. Lenskart Solutions Limited was incorporated in 2008 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Peyush Bansal
Headquarters
Gurugram
Employees
19,201
Website
lenskart.comExchange
View on NSE ↗Key stats
Market cap
₹1.23 L Cr
P/E ratio (TTM)
191.9
Dividend yield
0.00%
EPS (TTM)
₹3.70
Beta (1Y · daily vs NIFTY 50)
0.53
Shares float
75.52 Cr
EPS · quarter ended Jun 2026
₹1.28
Financial Performance
01 · Financials
EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21, FY22, FY23 and FY24 (revenue was nil or not reported).
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
Left off as not meaningful (growth from a very small base, beyond ±400%): Fixed assets FY23 (+681%).
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | — | — | ₹6,492.68 Cr | ₹8,814.04 Cr | |
EBITDA | — | — | — | — | ₹1,327.82 Cr | ₹1,911.57 Cr |
| ₹29.00 Cr | ₹-102.00 Cr | ₹-64.00 Cr | ₹-17.00 Cr | ₹295.59 Cr | ₹493.61 Cr | |
Diluted EPS | — | — | — | — | ₹1.72 | ₹2.8 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹493.61 Cr while the annual report gives ₹475.88 Cr (3.6% apart).
EBITDA for Mar 2026 could not be checked against the company's own annual report: this page shows ₹1,911.57 Cr while the annual report gives ₹1,164.45 Cr (39.1% apart).
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,802.00 Cr | ₹3,700.00 Cr | ₹9,462.00 Cr | ₹9,487.00 Cr | ₹10,390.00 Cr | ₹14,245.00 Cr | |
| — | — | — | — | ₹2,572.77 Cr | ₹3,096.60 Cr | |
Stockholders' equity | ₹2,378.00 Cr | ₹2,933.00 Cr | ₹5,456.00 Cr | ₹5,482.00 Cr | ₹5,931.00 Cr | ₹8,738.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-117.00 Cr | ₹-183.00 Cr | ₹95.00 Cr | ₹487.00 Cr | ₹1,231.00 Cr | ₹1,670.00 Cr | |
Investing cash flow | — | — | — | — | — | ₹-2,724.80 Cr |
| ₹-16.00 Cr | ₹604.00 Cr | ₹2,777.00 Cr | ₹-722.00 Cr | ₹-535.00 Cr | ₹1,201.00 Cr | |
Capital expenditure | ₹-111.00 Cr | ₹-248.00 Cr | ₹-413.00 Cr | ₹-438.00 Cr | ₹-427.00 Cr | ₹-828.00 Cr |
End cash position | — | — | — | — | — | ₹973.30 Cr |
Change in working capital, Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|
| Promoter | 17.57% | 17.55% | 17.53% |
| Public | 82.01% | 82.03% | 82.05% |
| Employee trusts | 0.42% | 0.42% | 0.42% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.